B
ALXN

Baird’s Alexion Pharmaceuticals ALXN Stock Holding History

Baird’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$5.76M Buy
33,216
+14,542
+78% +$2.63M 0.06% 312
2014
Q4 		$3.46M Sell
18,674
-2,051
-10% -$380K 0.04% 425
2014
Q3 		$3.44M Buy
20,725
+439
+2% +$72.1K 0.05% 329
2014
Q2 		$3.17M Sell
20,286
-164,256
-89% -$25.9M 0.04% 365
2014
Q1 		$28.1M Buy
184,542
+44,819
+32% +$7.13M 0.41% 76
2013
Q4 		$18.6M Buy
139,723
+20,431
+17% +$2.45M 0.32% 80
2013
Q3 		$13.9M Buy
119,292
+11,567
+11% +$1.27M 0.26% 102
2013
Q2 		$9.94M Buy
+107,725
New +$10.4M 0.2% 142

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Baird's ALXN Position: Q1 2015 in Review

Baird increased its Alexion Pharmaceuticals (ALXN) stake by 78% in Q1 2015, buying an estimated $2.63M and bringing the position to 33,216 shares worth $5.76M. The position accounts for 0.06% of the portfolio, ranked #312.

Baird first reported a position in ALXN in Q2 2013 and has held it in 8 quarters since. The position peaked at $28.1M in Q1 2014. 565 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

  • Baird held 33,216 shares of Alexion Pharmaceuticals worth $5.76M as of Q1 2015.
  • Baird bought 14,542 Alexion Pharmaceuticals shares in Q1 2015, an estimated $2.63M.
  • Alexion Pharmaceuticals made up 0.06% of Baird's portfolio in Q1 2015, its #312 holding.
  • Baird first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 8 quarters since.
  • Baird's Alexion Pharmaceuticals position peaked at $28.1M in Q1 2014.
  • 565 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.